Skip to content

Clinical efficacy and immune mechanism of yifeiyin in delaying TKI resistance in non-small cell lung cancer

Clinical efficacy and immune mechanism of yifeiyin in delaying TKI resistance in non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003377
Enrollment
Unknown
Registered
2020-06-07
Start date
2021-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Sponsors

Tongde Hospital of Zhejiang Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patient with stage IIIB to IV lung cancer which was diagnosed by CT, MRI, B-ultrasound and other imaging examinations, and confirmed by cytology or pathological examination; 2. Adopted the ADx-ARMS-EGFR gene mutation detection kit (Xiamen Aide Biomedical Science and Technology Co., Ltd. 21 human EGFR gene mutation detection kits) to be confirmed as EGFR gene sensitive mutation patients undergoing EGFR-TKI treatment; 3. TCM syndrome differentiation belongs to spleen deficiency phlegm and dampness type; 4. Can follow the doctor's instructions (take spleen deficiency phlegm and dampness medicine for more than 3 months), insist on taking medicine, good compliance, can understand the situation of this study Patients who have signed an informed consent form; 5. Age 18 to 70 years; PS score =9 g/L, neutrophil absolute cell count (ANC) >=1.5x10^9/L, platelet >=100x10^9/L, Bilirubin <=1.5 ULN, alkaline phosphatase ((APL), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.5 ULN (if liver metastasis is allowed ALT <=5 ULN ). International normalized ratio (INR) <=1.5 ULN. Activated partial thromboplastin time (APTT) <=1.2 ULN, creatinine <=1.5 ULN.

Exclusion criteria

Exclusion criteria: 1. Have a history of other tumors within 5 years; 2. Those whose expected survival time is less than 3 months; 3. Patients with any acute or chronic diseases or mental disorders or abnormal laboratory tests, these combined diseases may increase the risk of participating in research or research medication, or have an impact on the research results. The investigator judges that the patient is not suitable for joining the study,these situations include:(Uncontrolled high blood pressure, unstable angina, myocardial infarction, or symptomatic congestive heart failure or uncontrolled arrhythmia in the past 12 months. Electrocardiogram suggests significant changes in ischemia; bacterial, fungal, or viral infections The active period of the disease; those with dementia or major changes in mental state that make it impossible to understand or express informed consent); 4. Patients during pregnancy or lactation; 5. Those who have poor compliance with the protocol and the researchers believe that it is not appropriate to participate in this experiment; 6. Those who are allergic to drugs or are participating in other drug trials.

Design outcomes

Primary

MeasureTime frame
Progression free survival (PFS);Drug resistance;

Secondary

MeasureTime frame
Changes of TCM symptom score;Adverse reactions;

Countries

China

Contacts

Public ContactChai Kequn

Tongde Hospital of Zhejiang Province

ckqmzygzs@163.com+86 13906503739

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026